The levels of plasma lncRNAs, H19, HOX antisense intergenic RNA (HOTAIR), and metastasis associated lung adenocarcinoma transcript-1 (MALAT1), were analyzed in patients with gastric cancer (GC) and healthy controls.

H19 expression could serve as an independent prognostic factor for overall survival of non-small-cell lung cancer.

H19 can promote cell cycle progression of non-small cell lung cancer cells by down-regulating miR-107.

H19 may regulate non-small cell lung cancer (NSCLC) metastasis through modulating cellular signaling pathway proteins related to cell proliferation and cell adhesion, including MACC1, EGFR, beta-catenin and ERK1/2.

Results showed that lncRNA H19 was overexpressed in lung adenocarcinoma and was correlated with TNM stage, metastasis and acquired resistance to cisplatin. The data provide evidence that H19-mediated regulation of cisplatin resistance in human lung adenocarcinoma cells.

H19 depresses miR-196b to elevate LIN28B, resulting in accelerating cell proliferation in lung cancer.

The polymorphism rs2107425 in H19 gene was associated with the risk of lung cancer among female who never smokes in Shenyang, China.

Study demonstrated that H19 was highly expressed in non-small cell lung cancer (NSCLC), which promotes NSCLC development by regulating NF1 via competitive binding to microRNA-107.

H19 promoted gefitinib resistance of nonsmall cell lung cancer cells by packaging into exosomes.

the results of the present study indicated that lncRNA H19/miR29b3p/STAT3 signaling was involved in the development of lung adenocarcinoma

The miRNA hsa-miR-6515-3p potentially contributes to lncRNA H19-mediated-lung cancer metastasis.

Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer.

H19 lncRNA SNP rs2067051 was associated with a significantly decreased risk of non-small cell lung cancer (NSCLC) while rs217727 was related to significantly increased NSCLC susceptibility in a Chinese population.

Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma.

FOXF2 aggravates the progression of non-small cell lung cancer through targeting lncRNA H19 to downregulate PTEN.

LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.

The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of lung Adenocarcinoma.